New PET scan tracer aims to spot blood cancers more clearly

NCT ID NCT07670949

Recruiting now Diagnosis Sponsor: Zhejiang Cancer Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing a new radioactive tracer called 68Ga-EV203 for PET/CT scans in people with blood cancers like multiple myeloma, lymphoma, and leukemia. The goal is to see how the tracer spreads in the body, how much radiation it gives off, and whether it can find tumors better than the standard FDG tracer. Thirty participants will receive one injection and have four scans over two hours, plus a follow-up FDG scan a few days later.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 68Ga-EV203 injection (a radioactive tracer for PET/CT imaging)
What this could lead to: If successful, this could lead to a more accurate imaging method for detecting certain blood cancers, potentially improving diagnosis and treatment planning.
What could go wrong: This is an early-phase study with only 30 participants, so results may not apply to everyone. The new tracer may not prove significantly better than existing scans, and there are unknown risks from the radioactive injection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia hematopoietic and lymphoid cell neoplasm non-Hodgkin lymphoma plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEMATOLOGICAL MALIGNANCIES B

Contacts and locations

Locations

Zhejiang Cancer Hospital
RECRUITING

Hangzhou, Zhejiang, 310022, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.